Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Br J Pharmacol
2001 Jan 01;1322:381-4. doi: 10.1038/sj.bjp.0703861.
Show Gene links
Show Anatomy links
Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells.
Wickenden AD
,
Zou A
,
Wagoner PK
,
Jegla T
.
???displayArticle.abstract???
Heteromeric KCNQ5/Q3 channels were stably expressed in Chinese Hamster ovary cells and characterized using the whole cell voltage-clamp technique. KCNQ5/Q3 channels were activated by the novel anticonvulsant, retigabine (EC(50) 1.4 microM) by a mechanism that involved drug-induced, leftward shifts in the voltage-dependence of channel activation (-31.8 mV by 30 microM retigabine). KCNQ5/Q3 channels were inhibited by linopirdine (IC(50) 7.7 microM) and barium (IC(50) 0.46 mM), at concentrations similar to those required to inhibit native M-currents. These findings identify KCNQ5/Q3 channels as a molecular target for retigabine and raise the possibility that activation of KCNQ5/Q3 channels may be responsible for some of the anti-convulsant activity of this agent. Furthermore, the sensitivity of KCNQ5/Q3 channels to linopirdine supports the possibility that potassium channels comprised of KCNQ5 and KCNQ3 may make a contribution to native M-currents.
Aiken,
Reduction of spike frequency adaptation and blockade of M-current in rat CA1 pyramidal neurones by linopirdine (DuP 996), a neurotransmitter release enhancer.
1995, Pubmed
Aiken,
Reduction of spike frequency adaptation and blockade of M-current in rat CA1 pyramidal neurones by linopirdine (DuP 996), a neurotransmitter release enhancer.
1995,
Pubmed
Jentsch,
Neuronal KCNQ potassium channels: physiology and role in disease.
2000,
Pubmed
Jow,
Cloning and functional expression of rKCNQ2 K(+) channel from rat brain.
2000,
Pubmed
,
Xenbase
Kharkovets,
KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway.
2000,
Pubmed
Kubisch,
KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness.
1999,
Pubmed
,
Xenbase
Lamas,
Effects of a cognition-enhancer, linopirdine (DuP 996), on M-type potassium currents (IK(M)) and some other voltage- and ligand-gated membrane currents in rat sympathetic neurons.
1997,
Pubmed
Lerche,
Molecular cloning and functional expression of KCNQ5, a potassium channel subunit that may contribute to neuronal M-current diversity.
2000,
Pubmed
,
Xenbase
Main,
Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine.
2000,
Pubmed
,
Xenbase
Noda,
Inhibition of M-type K+ current by linopirdine, a neurotransmitter-release enhancer, in NG108-15 neuronal cells and rat cerebral neurons in culture.
1998,
Pubmed
Robbins,
Kinetic and pharmacological properties of the M-current in rodent neuroblastoma x glioma hybrid cells.
1992,
Pubmed
Rostock,
D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures.
1996,
Pubmed
Rundfeldt,
The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells tranfected with human KCNQ2/3 subunits.
2000,
Pubmed
Schroeder,
KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents.
2000,
Pubmed
Selyanko,
Two types of K(+) channel subunit, Erg1 and KCNQ2/3, contribute to the M-like current in a mammalian neuronal cell.
1999,
Pubmed
Wang,
KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel.
1998,
Pubmed
,
Xenbase
Wickenden,
Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels.
2000,
Pubmed
